To be able to describe the mechanisms of resistance to receptor tyrosine kinase antagonists (monoclonal antibodies and small molecule tyrosine kinase inhibitors)
Level
This learning outcome is a primary level outcome.
Sessions
This learning outcome is taught in the following sessions:
-
Cancer Week (Year 2)
- Lecture: Targeted Therapy
